Patent · US Active

RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

US11732266B2 · kind B2 · utility

0Cited by

0References

34Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Michael OLLMANN · San Carlos, US
Yang Li · Santa Clara, US
Jun Zhang · Xiamen, CN
Oliver HOMANN · Berkeley, US
Leslie P. Miranda · Thousand Oaks, US
Justin K. MURRAY · Madison, US
Bin Wu · Thousand Oaks, US
Oh Kyu YOON · Pacifica, US
John Gordon Allen · Newbury Park, US
Chawita Netirojjanakul · Longmont, US
Yuan Cheng · Newbury Park, US

Key dates

Filing date	Oct 26, 2020
Grant date	Aug 22, 2023
Priority date	—
Expiry date	Jan 24, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3513
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.